SynAct Pharma AB (publ) (“SynAct”) today announced that its Chief Financial Officer, Patrik Renblad has resigned and will move to a new assignment outside of the company. He will leave SynAct by the end of July, 2023, at the latest.
Patrik Renblad joined SynAct in 2021 and has during his tenure been instrumental in preparing the company for and taking the step to a listing of the share at Nasdaq Stockholm’s main market, coordinating the acquisition of TXP Pharma and two financing rounds, bringing in 230 mSEK in proceeds.
The process to recruit a new Chief Financial Officer has been initiated.
The information was submitted for publication, through the agency of the contact persons set out below, at 8.00 am CET, February 1, 2023.